Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
Everest Medicines (1952.HK) has acquired the Greater China rights to LNZ100 (VIZZ) from Corxel Pharmaceuticals to develop and commercialize the presbyopia treatment. LNZ100, originally developed by LENZ Therapeutics (LENZ), is already approved and launched in the US. The Chinese NDA was submitted in September 2025, with approval expected in Q1 2027. The asset features a unique aceclidine mechanism that improves near vision without impairing distance vision, addressing a significant unmet need in the aging Chinese population.
Key figures
- Drug Name
- LNZ100 (VIZZ)
- Launch date us
- October 2025
- Approval date us
- July 2025
- Trial participants
- 300
- Improvement 2 lines 3hrs
- 88%
- Improvement 3 lines 3hrs
- 74%
- Improvement 2 lines 10hrs
- 61%
- Improvement 2 lines 30min
- 84%
- Improvement 3 lines 10hrs
- 30%
- Improvement 3 lines 30min
- 69%
- Nda submission date china
- September 2025
- Expected approval date china
- Q1 2027
- Primary endpoint achievement
- Yes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.